humira
abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - molimo pogledajte dokument s informacijama o proizvodu.
prospan sirup 0.7 g/100 ml sirup
salveo d.o.o. sarajevo - Сухи ekstrakt list bršljena - sirup - 0.7 g/100 ml - 1 ml oralne otopine sadrži: 7 mg suhog ekstrakta lista bršljana (57.5:1)
prospan sirup 7 mg/1 ml sirup
salveo d.o.o. sarajevo - Сухи ekstrakt list bršljena - sirup - 7 mg/1 ml - 100 ml oralne otopine sadrži: 0,7 g suhog ekstrakta lista bršljana (57.5:1)
sinolpan forte 200 mg/1 kapsula gastrorezistentna kapsula, meka
salveo d.o.o. sarajevo - cineol - gastrorezistentna kapsula, meka - 200 mg/1 kapsula - 1 gastrorezistentna meka kapsula sadrži:200 mg cineola
sinolpan forte 200 mg/1 kapsula gastrorezistentna kapsula, meka
salveo d.o.o. sarajevo - cineol - gastrorezistentna kapsula, meka - 200 mg/1 kapsula - 1 gastrorezistentna meka kapsula sadrži: 200 mg cineola
sinolpan 100 mg/1 mkapsula gastrorezistentna kapsula, meka
salveo d.o.o. sarajevo - cineol - gastrorezistentna kapsula, meka - 100 mg/1 mkapsula - 1 gastrorezistentna meka kapsula sadrži: 100 mg cineola
lumigan
abbvie deutschland gmbh & co. kg - bimatoprost - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - smanjenje povišenog intraokularnog tlaka u kroničnom otvorenom kutu glaukoma i očne hipertenzije (kao monoterapija ili kao dodatna terapija beta-blokatora).
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
polinol 25 mg/1 tableta+ 25 mg/1 tableta+ 25 mg/1 tableta tableta
alpen pharma d.o.o. - cardiospermum, galfimia Глаука diehl. d3, Д4 люффы operculata Трит. - tableta - 25 mg/1 tableta+ 25 mg/1 tableta+ 25 mg/1 tableta - jedna tableta sadrži: 25 mg luffa operculata trit. d4 25 mg galphimia glauca trit. d3 25 mg cardiospermum trit. d3
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - imunosupresivi - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.